Tafinlar (dabrafenib) is a small molecule pharmaceutical. Dabrafenib was first approved as Tafinlar on 2013-05-29. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf. Tafinlar's patents are valid until 2033-08-30 (FDA).
|Drug Class||Raf kinase inhibitors|